Guillaume Adrien, Chiodini Benedetta, Adams Brigitte, Dahan Karin, Deschênes Georges, Ismaili Khalid
Department of Neonatology, Hôpital Erasme, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Department of Pediatric Nephrology, Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Front Pediatr. 2021 Apr 20;9:615183. doi: 10.3389/fped.2021.615183. eCollection 2021.
Oxalate overproduction in Primary Hyperoxaluria type I (PH1) leads to progressive renal failure and systemic oxalate deposition. In severe infantile forms of PH1 (IPH1), end-stage renal disease (ESRD) occurs in the first years of life. Usually, the management of these infantile forms is challenging and consists in an intensive dialysis regimen followed by a liver-kidney transplantation (combined or sequential). Medical records of all infants with IPH1 reaching ESRD within the first year of life, diagnosed and followed between 2005 and 2018 in two pediatric nephrology departments in Brussels and Paris, have been reviewed. Seven patients were included. They reached ESRD at a median age of 3.5 (2-7) months. Dialysis was started at a median age of 4 (2-10 months). Peritoneal dialysis (PD) was the initial treatment for 6 patients and hemodialysis (HD) for one patient. Liver transplantation (LT) was performed in all patients and kidney transplantation (KT) in six of them. A sequential strategy has been chosen in 5 patients, a combined in one. The kidney transplanted as part of the combined strategy was lost. Median age at LT and KT was 25 (10-41) months and 32.5 (26-75) months, respectively. No death occurred in the series. At the end of a median follow-up of 3 years, mean eGFR was 64 ± 29 ml/min/1.73 m. All patients presented retinal and bone lesions and five patients presented bones fractures. Despite encouraging survival figures, the morbidity in IPH1 patients remains extremely heavy and its management presents a huge challenge. Thanks to the newly developed RNA-interference drug, the future holds brighter prospects.
I型原发性高草酸尿症(PH1)中草酸盐产生过多会导致进行性肾衰竭和全身性草酸盐沉积。在严重的婴儿型PH1(IPH1)中,终末期肾病(ESRD)在生命的最初几年就会出现。通常,这些婴儿型疾病的管理具有挑战性,包括强化透析方案,随后进行肝肾联合移植(联合或序贯)。回顾了2005年至2018年间在布鲁塞尔和巴黎的两个儿科肾脏病科诊断并随访的所有在生命第一年达到ESRD的IPH1婴儿的病历。纳入了7名患者。他们达到ESRD的中位年龄为3.5(2 - 7)个月。透析开始的中位年龄为4(2 - 10)个月。6例患者初始治疗为腹膜透析(PD),1例为血液透析(HD)。所有患者均进行了肝移植(LT),其中6例进行了肾移植(KT)。5例患者选择了序贯策略,1例选择了联合策略。作为联合策略一部分移植的肾脏失功。LT和KT的中位年龄分别为25(10 - 41)个月和32.5(26 - 75)个月。该系列中无死亡病例。中位随访3年后,平均估算肾小球滤过率(eGFR)为64±29 ml/min/1.73 m²。所有患者均出现视网膜和骨骼病变,5例患者出现骨折。尽管生存数据令人鼓舞,但IPH1患者的发病率仍然极高,其管理面临巨大挑战。得益于新开发的RNA干扰药物,未来前景更加光明。